reason report
adopt momentum continu build dash launch
bottom line today market close deliv solid quarter
sale out-performance sale y/i --
ahead us consensu repres beat
last quarter consecut also compani
quarter --
growth acceler
come easier comp sale growth even acceler
point comp-adjust basi beat almost entir driven
omnipod us highlight on-going adopt momentum
rais sale guidanc midpoint
suggest growth y/i previous
quarterli beat overal clean beat rais
quarter reinforc view drive sustain
double-digit growth forese futur seem
sustain high-teen instal base growth rate
could acceler compani roll dash
shift pharmaci channel could potenti drive
acceler adopt new busi model effect
address barrier adopt elimin up-front cost
dash person diabet manag off-set higher price per
pod expand coverag dash cover live
 includ medicar vs exit
medicaid vs exit us speak
strength pay-as-you-go model believ
also acceler intern instal base
direct importantli underappreci growth
opportun insulin-depend type diabet see
mix type new add alreadi trend expect
patient segment grow estim less
penetr today market repres signific
reiter op pt pt appli
ev/sal multipl sale estim share
current trade sale estim expect
multipl hold current level given believ sustain
double-digit growth next year dramat
improv profit profil -- consist net incom posit
believ share deserv trade premium ev/
sale multipl smid-cap med-tech coverag univers
net debt total capit
medic suppli devic
sale
year price history/av daili volume mil
compani inform svb leerink llc research
revenu ep figur includ fa option expens
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
outlook move slightli higher still conserv
updat guidanc sale estim move
y/i omnipod
sale estim y/i fall high end guidanc
rang expect adopt momentum sustain
rate share outperform price target next
year continu focu drive strong referr momentum increas
sale forc product greater awar deliv believ around
nearli top-lin compound-annual-growth-rate time-frame ex neighborhood diabet insulet
underw manag transit four year ago busi stabilized-
to-acceler believ long-term market opportun pump therapi unchang
penetr type patient today solid execut
continu reinvest sale forc appear pois drive sustain re-
continu rate share op pt appli ev/sal multipl
sale estim share current trade sale
estim expect multipl hold current level given believ sustain
double-digit growth next year dramat improv profit profil --
consist net incom posit believ share deserv trade premium
ev/sal multipl smid-cap med-tech coverag univers
risk includ failur success execut adopt omnipod type patient
potenti manufactur issu and/or inabl seamlessli ramp product failur
advanc pipelin artifici pancrea product failur bring success drug
deliveri partnership commerci increas competit higher us dollar
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt svb leerink estim
dollar million except per share data
total good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item first order analyt
consensu
compani report factset consensu first order analyt svb leerink estim
dollar million except per share data
total good sold
research develop expens
loss discontinu oper
sg sale
 sale
oper expens sale
compani report svb leerink estim
declin
increas
mid rang
mid rang
mid-low teen growth
mid-low teen growth
teen
 y/i midpoint
dexcom cgm provid
autom glucos control
essenti enabl omnipod
cgm speak one
clinic trial on-go
august stare studi enrol
patient expect complet octob
august expect complet trial
move final pre-pivot
august track start pivot
 novemb horizon integr pump/cgm
push late plan
add phone control
start
enrol complet
believ possibl present data
ada
may expect data avail
run clinic trial full
 may expect submit week
actual
market two decad
good deliveri
system avail eli lilli
launch kwikpen late
pump avail market u-
effect increas
capac reservoir
enabl omnipod better serv
peopl higher insulin
requir peopl live
insulin depend type
diabet omnipod
omnipod doubl
